Response Genetics, Inc. Appoints John Ferrara to Its Board of Directors

Business Wire, April 10, 2008

LOS ANGELES -- Response Genetics, Inc. (NASDAQ: RGDX), a company focused on the development of molecular diagnostic tests for cancer, announced today that John C. Ferrara has joined its Board of Directors.

Mr. Ferrara is currently the Chief Financial Officer (CFO) for EDGAR[R] Online[R], Inc. (NASDAQ: EDGR) a leading provider of value-added business and financial information on global companies to financial, corporate and advisory professionals. Prior to joining EDGAR Online, Mr. Ferrara served as Interim CFO to GAMCO Investors, Inc., President of The LGL Group, Inc. and has held CFO positions at Space Holding Corporation, Golden Books Family Entertainment and Renaissance Communications Corporation.

Since 1999, Mr. Ferrara has served on the Board of Directors of several public companies, including GAMCO Investors and Lynch Interactive. Mr. Ferrara holds a B.S. in Accounting from the University of Maryland and an M.B.A. in Finance from Columbia University.

"Response Genetics is pleased to welcome John Ferrara as a new member on our Board of Directors," said Kathleen Danenberg, CEO and President of Response Genetics, Inc. "John's extensive financial experience expands the depth and breadth of Response Genetics' board. We look forward to his involvement and contributions to the Company."

Mr. Ferrara's tenure on the Board commenced April 4, 2008.

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI") (the "Company") (NASDAQ: RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, the ability of the Company to make its ResponseDx:Lung[TM] and ResponseDX:Colon[TM] tests available in a number of institutions, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.